Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, John Radcliffe Hospital, Headington, Oxford, OX3 9DU Are you passionate about the future of genetic medicines? Do you want to contribute to pioneering research with real translational potential? Join the Gene Medicine Group at the University of Oxford and help shape the future of gene therapy. We’re developing a next-generation delivery platform using Lentivirus-derived nanoparticles engineered to package CRISPR RNPs instead of viral genomes. This platform offers high potency, with improved safety, avoiding insertional mutagenesis and minimizing genotoxicity. This is an exciting opportunity to be part of a cutting-edge project developing next-generation genome editing therapies. In this role you will support the incorporation of third-generation genome editors into LVNPs, to correct ‘gain-of-function’ mutations through gene correction or replacement strategies. You will help refine a scalable, cGMP-compliant manufacturing pipeline and contribute to disease modelling using iPSCs and in vivo delivery studies. This is a unique opportunity to be part of a translational research programme advancing gene editing tools towards clinical application. Start date: Summer 2025 Closing date: 12 noon, 8 May 2025 Interviews: Week commencing 26 May 2025 Committed to equality and valuing diversity.